CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.96 USD | +2.24% |
|
+6.89% | -9.01% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,621 | 10,818 | 5,799 | 3,183 | 4,972 | 4,729 | - | - |
| Enterprise Value (EV) 1 | 2,677 | 9,649 | 3,420 | 1,367 | 3,277 | 2,839 | 3,093 | 3,240 |
| P/E ratio | 52.1 x | -28.9 x | 15.2 x | -4.86 x | -32.3 x | -10.1 x | -12.4 x | -27.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.5 x | 15,045 x | 6.34 x | 2,657 x | 13.4 x | 57.8 x | 14.8 x | 5.59 x |
| EV / Revenue | 9.25 x | 13,420 x | 3.74 x | 1,141 x | 8.83 x | 34.7 x | 9.65 x | 3.83 x |
| EV / EBITDA | 52 x | -27.9 x | 8.74 x | -2.11 x | -16.2 x | -7.19 x | -10.4 x | 17.6 x |
| EV / FCF | - | -37.6 x | 7.48 x | -2.57 x | -12.1 x | -10.4 x | -8.91 x | -12.2 x |
| FCF Yield | - | -2.66% | 13.4% | -39% | -8.24% | -9.59% | -11.2% | -8.21% |
| Price to Book | - | 6.94 x | 2.4 x | 1.69 x | 2.63 x | 2.54 x | 2.88 x | 3.24 x |
| Nbr of stocks (in thousands) | 59,454 | 70,652 | 76,527 | 78,294 | 79,432 | 84,883 | - | - |
| Reference price 2 | 60.90 | 153.1 | 75.78 | 40.65 | 62.60 | 55.71 | 55.71 | 55.71 |
| Announcement Date | 2/12/20 | 2/16/21 | 2/15/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 289.6 | 0.719 | 915 | 1.198 | 371.2 | 81.76 | 320.4 | 845.5 |
| EBITDA 1 | 51.46 | -345.3 | 391.5 | -649 | -202.7 | -394.9 | -297 | 184.1 |
| EBIT 1 | 46.74 | -354.4 | 373.5 | -673.2 | -222.5 | -492.9 | -386.7 | -75.75 |
| Operating Margin | 16.14% | -49,295.55% | 40.82% | -56,190.4% | -59.95% | -602.88% | -120.71% | -8.96% |
| Earnings before Tax (EBT) 1 | 67.31 | -348.1 | 379.5 | -650.5 | -150.7 | -463.4 | -392.1 | -185.7 |
| Net income 1 | 66.86 | -348.9 | 377.7 | -650.2 | -153.6 | -448.7 | -392 | -179.8 |
| Net margin | 23.09% | -48,520.86% | 41.28% | -54,271.7% | -41.38% | -548.85% | -122.36% | -21.27% |
| EPS 2 | 1.170 | -5.290 | 4.970 | -8.360 | -1.940 | -5.540 | -4.495 | -2.054 |
| Free Cash Flow 1 | - | -256.7 | 457.3 | -532.9 | -269.8 | -272.3 | -347.3 | -265.9 |
| FCF margin | - | -35,705.7% | 49.98% | -44,484.89% | -72.69% | -333.07% | -108.39% | -31.44% |
| FCF Conversion (EBITDA) | - | - | 116.8% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 121.08% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/12/20 | 2/16/21 | 2/15/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.9 | 0.94 | 0.158 | 0.094 | 0.006 | 100 | 70 | - | 201.2 | 0.504 | 3.996 | 17.18 | 32.24 | 22.81 | 33.89 |
| EBITDA 1 | - | - | - | - | - | - | - | - | 74.48 | - | -115.5 | -116.5 | -112.2 | - | - |
| EBIT 1 | -145.7 | -176 | -183.3 | -182.4 | -131.5 | -64.49 | -95.22 | -132.4 | 69.58 | -140.6 | -144.7 | -133.1 | -126.1 | -133.8 | -134.8 |
| Operating Margin | -1,129.53% | -18,720.43% | -115,987.34% | -194,029.79% | -2,192,350% | -64.49% | -136.03% | - | 34.58% | -27,894.25% | -3,620.91% | -774.74% | -391.08% | -586.55% | -397.64% |
| Earnings before Tax (EBT) 1 | -143.5 | -175.6 | -179.7 | -175.1 | -120.1 | -51.74 | -76.82 | -111.7 | 89.58 | -115.9 | -125.4 | -113.8 | -108.6 | -126.6 | -124 |
| Net income 1 | -141.2 | -179.2 | -185.8 | -174.5 | -110.6 | -53.06 | -77.74 | -112.2 | 89.35 | -116.6 | -127.5 | -115.2 | -111 | -127 | -124.3 |
| Net margin | -1,095.03% | -19,065.64% | -117,616.46% | -185,690.43% | -1,842,916.67% | -53.06% | -111.06% | - | 44.41% | -23,133.13% | -3,191.33% | -670.47% | -344.18% | -556.69% | -366.87% |
| EPS 2 | -1.840 | -2.320 | -2.400 | -2.240 | -1.410 | -0.6700 | -0.9800 | -1.410 | 1.100 | -1.430 | -1.524 | -1.384 | -1.342 | -1.450 | -1.389 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/15/22 | 5/9/22 | 8/8/22 | 11/1/22 | 2/21/23 | 5/8/23 | 8/7/23 | 11/6/23 | 2/21/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 944 | 1,169 | 2,379 | 1,815 | 1,696 | 1,890 | 1,636 | 1,489 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -257 | 457 | -533 | -270 | -272 | -347 | -266 |
| ROE (net income / shareholders' equity) | - | -26.8% | 18.6% | -30.4% | -8.17% | -20.3% | -4.57% | 4.26% |
| ROA (Net income/ Total Assets) | - | - | - | -26% | -6.87% | -15.1% | 4.55% | 12.3% |
| Assets 1 | - | - | - | 2,497 | 2,236 | 2,972 | -8,616 | -1,462 |
| Book Value Per Share 2 | - | 22.10 | 31.60 | 24.10 | 23.80 | 21.90 | 19.40 | 17.20 |
| Cash Flow per Share 2 | - | -3.610 | 6.700 | -6.380 | -3.290 | -1.970 | 0.3000 | 6.540 |
| Capex 1 | - | 18.4 | 81.7 | 37.2 | 9.47 | 10.6 | 15.7 | 16.6 |
| Capex / Sales | - | 2,553.27% | 8.93% | 3,104.17% | 2.55% | 12.92% | 4.89% | 1.97% |
| Announcement Date | 2/12/20 | 2/16/21 | 2/15/22 | 2/21/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
55.71
USD
Average target price
86.78
USD
Spread / Average Target
+55.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.01% | 4.73B | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +43.45% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- CRSP Stock
- Financials CRISPR Therapeutics AG